AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2691100 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose steroids (125 mg methylprednisolone I.M. the night before and morning of PTCA, and prednisone 60 mg p.o. Q.D. for 1 week post-PTCA)
Number of subjects: 102
Study 2691100 — intervention group
Group type: COMPARATOR
Intervention: No steroids (control group)
Number of subjects: 102
Study 2691100 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose steroids
Number of subjects: 102
Study 31930507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 465
Study 31930507 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychoanalytic psychotherapy
Number of subjects: 465
Study 31930507 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychosocial intervention
Number of subjects: 465
Study 31930507 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 465
Study 31930507 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 465
Study 31930507 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessions-compulsions
Number of subjects: 465
Study 31930507 — intervention group
Group type: EXPERIMENTAL
Intervention: Conduct problems
Number of subjects: 465
Study 31930507 — intervention group
Group type: EXPERIMENTAL
Intervention: General psychopathology
Number of subjects: 465
Study 31552774 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using logistic regression with lasso regularization for predicting early death after radical cystectomy.
Number of subjects: 1099
Study 29095069 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Number of subjects: 8
Study 29095069 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo)
Number of subjects: 8
Study 26959652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (OHB)
Number of subjects: 11
Study 26959652 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (Control)
Number of subjects: 11
Study 24015889 — intervention group
Group type: EXPERIMENTAL
Intervention: Large, red stopwatch timer attached to the stretcher upon arrival (ON blocks)
Number of subjects: 0
Study 24015889 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without stopwatch timer (OFF blocks)
Number of subjects: 0
Study 22891875 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive
Number of subjects: 0
Study 22891875 — intervention group
Group type: EXPERIMENTAL
Intervention: Abridged questionnaire
Number of subjects: 0
Study 22891875 — intervention group
Group type: COMPARATOR
Intervention: Full length questionnaire
Number of subjects: 0
Study 22891875 — intervention group
Group type: EXPERIMENTAL
Intervention: Full questionnaire reminder
Number of subjects: 0
Study 22891875 — intervention group
Group type: COMPARATOR
Intervention: Postcard reminder
Number of subjects: 0
Study 22891875 — intervention group
Group type: EXPERIMENTAL
Intervention: Abridged questionnaire reminder
Number of subjects: 0
Study 22891875 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcard reminder followed by abridged questionnaire
Number of subjects: 0
Study 22891875 — intervention group
Group type: EXPERIMENTAL
Intervention: Full/full/abridged questionnaire
Number of subjects: 0
Study 22891875 — intervention group
Group type: EXPERIMENTAL
Intervention: Abridged questionnaire after postcard reminder
Number of subjects: 0
Study 20072614 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 4895
Study 20072614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4895
Study 17540638 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 0.75% gel
Number of subjects: 67
Study 17540638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 16316969 — intervention group
Group type: EXPERIMENTAL
Intervention: IV amiodarone (low dose)
Number of subjects: 61
Study 16316969 — intervention group
Group type: EXPERIMENTAL
Intervention: IV amiodarone (medium dose)
Number of subjects: 61
Study 16316969 — intervention group
Group type: EXPERIMENTAL
Intervention: IV amiodarone (high dose)
Number of subjects: 61
Study 16316969 — intervention group
Group type: EXPERIMENTAL
Intervention: IV amiodarone (all doses)
Number of subjects: 61
Study 11874387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 21
Study 11874387 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 21
Study 11874387 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (D)
Number of subjects: 21
Study 9798810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 17
Study 9798810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 9798810 — intervention group
Group type: EXPERIMENTAL
Intervention: Late evening meal (provocative)
Number of subjects: 17
Study 10218598 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane group (patients with preceding isoflurane exposure)
Number of subjects: 22
Study 10218598 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without preceding isoflurane exposure)
Number of subjects: 22
Study 1914758 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dose antacid (magaldrate) 88 mmol/day, given in three divided doses (10 ml after breakfast and lunch, 20 ml at bedtime) for eight weeks
Number of subjects: 0
Study 1914758 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg/day, given in two divided doses (400 mg after breakfast and 400 mg at bedtime) for eight weeks
Number of subjects: 0
Study 1914758 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dose antacid (magaldrate) 88 mmol/day, given in two schedules for four weeks
Number of subjects: 0
Study 1914758 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg/day, given in two divided doses for four weeks
Number of subjects: 0
Study 6136936 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg temazepam
Number of subjects: 12
Study 6136936 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg temazepam
Number of subjects: 12
Study 6136936 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg temazepam
Number of subjects: 12
Study 6136936 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 12
Study 6136936 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nitrazepam
Number of subjects: 12
Study 6136936 — intervention group
Group type: EXPERIMENTAL
Intervention: temazepam
Number of subjects: 12
Study 6136936 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrazepam
Number of subjects: 12
Study 6136936 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31892489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab emtansine (T-DM1)
Number of subjects: 1620
Study 30664277 — intervention group
Group type: EXPERIMENTAL
Intervention: TME with preservation of Denonvilliers' fascia (P group)
Number of subjects: 20
Study 30664277 — intervention group
Group type: COMPARATOR
Intervention: TME with resection of Denonvilliers' fascia (R group)
Number of subjects: 20
Study 27819537 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote stretching of the lower limb (LLS)
Number of subjects: 63
Study 27819537 — intervention group
Group type: EXPERIMENTAL
Intervention: Local stretching of the cervical spine (CSS)
Number of subjects: 63
Study 27819537 — intervention group
Group type: COMPARATOR
Intervention: Inactive control (CON)
Number of subjects: 63
Study 26897614 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief substance use intervention
Number of subjects: 0
Study 27103495 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention (Physical Activity 4 Everyone)
Number of subjects: 1150
Study 27103495 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1150
Study 23511299 — intervention group
Group type: EXPERIMENTAL
Intervention: NR100157
Number of subjects: 340
Study 23511299 — intervention group
Group type: COMPARATOR
Intervention: Control (isocaloric and isonitrogenous)
Number of subjects: 340
Study 21569345 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership for Health‐2 (PFH‐2) smoking cessation intervention
Number of subjects: 374
Study 19797436 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model
Number of subjects: 306
Study 19797436 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study 16427932 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg
Number of subjects: 45
Study 16427932 — intervention group
Group type: COMPARATOR
Intervention: No erythromycin (Control)
Number of subjects: 45
Study 14657045 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure in humans
Number of subjects: 22
Study 14657045 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of sympathetic nerves in rats
Number of subjects: 22
Study 14657045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic activation during rhythmic muscle contraction
Number of subjects: 22
Study 11369066 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate cream (MMF) applied twice a week from the start of radiotherapy until the 12th fraction (24 Gy) and thereafter once daily until 3 weeks after completion of radiation, in combination with daily emollient cream
Number of subjects: 49
Study 11369066 — intervention group
Group type: COMPARATOR
Intervention: Emollient cream applied daily
Number of subjects: 49
Study 15532307 — intervention group
Group type: COMPARATOR
Intervention: Magnesium orotate (magnerot)
Number of subjects: 32
Study 7646200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved aortic or pulmonary homograft (n = 38)
Number of subjects: 101
Study 7646200 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless porcine aortic valve xenograft (Edwards Prima 2500) (n = 63)
Number of subjects: 101
Study 2513790 — intervention group
Group type: EXPERIMENTAL
Intervention: Trinitrine (0.4 mg for <1 yr, 0.8 mg for >1 yr) applied to the puncture site
Number of subjects: 150
Study 2513790 — intervention group
Group type: COMPARATOR
Intervention: Vaseline applied to the puncture site
Number of subjects: 150
Study 2513790 — intervention group
Group type: COMPARATOR
Intervention: Trinitrine applied at a distance from the zone of puncture
Number of subjects: 150
Study 35059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (4.2 to 25 microgram/kg/min)
Number of subjects: 11
Study 35059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (6.22 microgram/kg/min)
Number of subjects: 11
Study 31416326 — intervention group
Group type: EXPERIMENTAL
Intervention: AROMA (Affordable Rapid Olfaction Measurement Array)
Number of subjects: 75
Study 31416326 — intervention group
Group type: EXPERIMENTAL
Intervention: AROMA
Number of subjects: 75
Study 31416326 — intervention group
Group type: COMPARATOR
Intervention: UPSIT (University of Pennsylvania Smell Identification Test)
Number of subjects: 75
Study 31416326 — intervention group
Group type: COMPARATOR
Intervention: UPSIT
Number of subjects: 75
Study 30170781 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotics (Ecologic®Barrier) 2.5 × 10^9 cfu/g, twice daily for 6 months
Number of subjects: 30
Study 28174153 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 140
Study 28174153 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 140
Study 28174153 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 140
Study 28174153 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine + 2% lidocaine (bupi+lido)
Number of subjects: 140
Study 25809236 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HP, 30% of energy)
Number of subjects: 18
Study 25809236 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (NP, 15% of energy)
Number of subjects: 18
Study 25809236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of protein and free amino acids (NPAA, each 15% of energy)
Number of subjects: 18
Study 25809236 — intervention group
Group type: COMPARATOR
Intervention: Three weight loss diets (HP, NP, NPAA)
Number of subjects: 18
Study 23445093 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial pancreas
Number of subjects: 56
Study 23445093 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented insulin pump (control)
Number of subjects: 56
Study 21751435 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of ropivacaine 0.5%
Number of subjects: 30
Study 21751435 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of ropivacaine 0.5%
Number of subjects: 30
Study 19346989 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 18
Study 19346989 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 18
Study 16707408 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 4-mg oral granules
Number of subjects: 1
Study 15504180 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125 mg i.v.
Number of subjects: 75
Study 15504180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg i.v. (active control)
Number of subjects: 75
Study 15504180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 11767265 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 40
Study 11767265 — intervention group
Group type: COMPARATOR
Intervention: Placebo consumption
Number of subjects: 40
Study 9261520 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m2 (30 min IV infusion on days 1, 8, 15 of a 28-day cycle)
Number of subjects: 146
Study 9261520 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 (day 1) and Etoposide 100 mg/m2 (days 1, 2, 3)
Number of subjects: 146
Study 9261520 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-etoposide
Number of subjects: 146
Study 9587343 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose Klean Prep
Number of subjects: 30
Study 9587343 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose Klean Prep
Number of subjects: 30
Study 9587343 — intervention group
Group type: COMPARATOR
Intervention: Picolax
Number of subjects: 30
Study 2702802 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 6
Study 2702802 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone
Number of subjects: 6
Study 14482 — intervention group
Group type: EXPERIMENTAL
Intervention: oxazepam (3 X 15 mg per day)
Number of subjects: 38
Study 14482 — intervention group
Group type: EXPERIMENTAL
Intervention: oxypertine (3 X 10 mg per day)
Number of subjects: 38
Study 31486158 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D (50,000 IU pearl cholecalciferol daily for 6 days)
Number of subjects: 72
Study 31486158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin D (1 injection of 300,000 IU cholecalciferol)
Number of subjects: 72
Study 31486158 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation)
Number of subjects: 72
Study 31934995 — intervention group
Group type: EXPERIMENTAL
Intervention: sampeginterferon beta 1a 180 μg
Number of subjects: 399
Study 31934995 — intervention group
Group type: EXPERIMENTAL
Intervention: sampeginterferon beta 1a 240 μg
Number of subjects: 399
Study 31934995 — intervention group
Group type: EXPERIMENTAL
Intervention: low dose interferon beta‐1a (LIB) 30 μg
Number of subjects: 399
Study 31934995 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 399
Study 28118668 — intervention group
Group type: EXPERIMENTAL
Intervention: High-blocking eyeglasses
Number of subjects: 36
Study 28118668 — intervention group
Group type: COMPARATOR
Intervention: Low-blocking eyeglasses
Number of subjects: 36
Study 28118668 — intervention group
Group type: COMPARATOR
Intervention: No-block eyeglasses
Number of subjects: 36
Study 24793222 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Behavioral Interventions and Supports
Number of subjects: 37
Study 24040864 — intervention group
Group type: EXPERIMENTAL
Intervention: Free primary and some referral care (prepayment scheme)
Number of subjects: 2592
Study 24040864 — intervention group
Group type: COMPARATOR
Intervention: User fees for healthcare (control group)
Number of subjects: 2592
Study 24040864 — intervention group
Group type: EXPERIMENTAL
Intervention: Free healthcare (using any clinic visit in the past month)
Number of subjects: 2592
Study 22082677 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic heparin anticoagulation
Number of subjects: 42
Study 22082677 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant women (control)
Number of subjects: 42
Study 19129911 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 733
Study 16763405 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (34‐40 Gy)
Number of subjects: 98
Study 16763405 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with chemotherapy including anthracycline
Number of subjects: 98
Study 15367070 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback reports and a multiple behavior manual at 0, 6, and 12 months
Number of subjects: 2460
Study 15367070 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 2460
Study 11736878 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (AmB) administered at 1 mg kg(‐1) day(‐1) in dextrose (doseform=1)
Number of subjects: 57
Study 11736878 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (AmB) administered at 1 mg kg(‐1) day(‐1) in lipid emulsion (doseform=2)
Number of subjects: 57
Study 11736878 — intervention group
Group type: COMPARATOR
Intervention: Covariate model predictions in validation group of 26 children
Number of subjects: 57
Study 9239585 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous propofol infusion (6 to 12 mg kg‐1 h‐1) during total intravenous anesthesia (TIVA)
Number of subjects: 18
Study 8322128 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysorb absorbable staples
Number of subjects: 94
Study 8322128 — intervention group
Group type: COMPARATOR
Intervention: Regular suture technique
Number of subjects: 94
Study 3092310 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV pH 6.8
Number of subjects: 38
Study 3092310 — intervention group
Group type: EXPERIMENTAL
Intervention: IGIV pH 4.25
Number of subjects: 38
Study 3092310 — intervention group
Group type: COMPARATOR
Intervention: IGIV pH 6.8 and IGIV pH 4.25
Number of subjects: 38
Study 29563781 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 250 µg once daily (OD) followed by 500 µg OD for 8 weeks
Number of subjects: 1321
Study 29563781 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 µg every other day (EOD) followed by 500 µg OD for 8 weeks
Number of subjects: 1321
Study 29563781 — intervention group
Group type: COMPARATOR
Intervention: Roflumilast 500 µg once daily (OD) for 8 weeks
Number of subjects: 1321
Study 27107302 — intervention group
Group type: COMPARATOR
Intervention: Abbreviated intervention delivered to control preschools
Number of subjects: 16
Study 25459040 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid coronary revascularization (HCR)
Number of subjects: 200
Study 25459040 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 200
Study 22317838 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid maneuver (HM)
Number of subjects: 88
Study 22317838 — intervention group
Group type: COMPARATOR
Intervention: Other maneuvers (Semont, Epley)
Number of subjects: 88
Study 22317838 — intervention group
Group type: EXPERIMENTAL
Intervention: All maneuvers evaluated
Number of subjects: 88
Study 20538833 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg/d
Number of subjects: 113
Study 20538833 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (Control)
Number of subjects: 113
Study 20538833 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol treatment
Number of subjects: 113
Study 18713932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infraclavicular block using the double bubble sign
Number of subjects: 70
Study 18713932 — intervention group
Group type: COMPARATOR
Intervention: Triple-stimulation axillary block
Number of subjects: 70
Study 15981754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen on intermittent positive pressure with nasal cannulae
Number of subjects: 617
Study 15981754 — intervention group
Group type: COMPARATOR
Intervention: Facial mask
Number of subjects: 617
Study 12915697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of pancreatic polypeptide (PP) at 10 pmol/kg/min
Number of subjects: 10
Study 10396494 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief self-completion dietary assessment tools based on food groups consumed during a week
Number of subjects: 111
Study 10396494 — intervention group
Group type: COMPARATOR
Intervention: Weighed dietary record
Number of subjects: 111
Study 8792761 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine augmentation
Number of subjects: 292
Study 1750480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nal-Glu (50 micrograms/kg intramuscularly for 3 to 4 days)
Number of subjects: 8
Study 1750480 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study 7066143 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable Rüsch tube with intermittent cuff volume adjustment (Group B)
Number of subjects: 184
Study 7066143 — intervention group
Group type: COMPARATOR
Intervention: Reusable Rüsch tube without cuff volume adjustment (Group C)
Number of subjects: 184
Study 7066143 — intervention group
Group type: COMPARATOR
Intervention: Disposable Portex Blue Line tube with intermittent cuff volume adjustment (Group D)
Number of subjects: 184
Study 7066143 — intervention group
Group type: COMPARATOR
Intervention: Disposable Shiley Low Pressure tube with intermittent cuff volume adjustment (Group E)
Number of subjects: 184
Study 7066143 — intervention group
Group type: COMPARATOR
Intervention: Mask only (Group A)
Number of subjects: 184
Study 31972580 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression therapy (71% of patients received this intervention)
Number of subjects: 160
Study 31972580 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment tools used (92% of files indicated use)
Number of subjects: 160